LifeNet Health’s decellularized pulmonary patch allograft utilizes Matracell®, a proprietary, patented and validated processing technology. Matracell removes a minimum of 97% of donor DNA, allowing for rapid cellular infiltration and re-vascularization.
- Clinical effectiveness - lower potential for reoperation or intervention1,2
- Patented, validated decellularization and disinfection process that removes ≥99% of donor DNA3
- Resists calcification and stenosis1,2
- Allografts most closely resemble native tissue, making them compliant, flexible and easy to handle
- Potentially reduces operationg room time and cost by reducing the rate of serious adverse events and reoperations4
Clinical Applications
- Right side/pulmonary outflow tract reconstruction
- Right ventricular obstruction
- Pulmonary atresis and other right ventricular outflow tract congential defects
Image - before/ after processing
1. Lofland GK, et al. Initial pediatric cardiac experience with decellularized allograft patches. Ann of Thoracic Surg, 2012;93:968-71
2. Hopkins RA, et al. Pulmonary Arterioplasty With Decellularized Allogeneic Patches. Ann of Thoracic Surg, Vol. 97, Issue 4, April 2014, Pages 1407-1412
3. LifeNet Health data on file: PQ-07-078
4. CardioGraft-MC (also known as Matracell®) Decellularized Cardiac Patch Allograft Cost-Effectiveness Analysis Musculoskeletal Clinical Regulatory Advisors, June 2014